Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 8/20 | 0.48 |
| ▸ | BRAF | P15056 | 8/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.43 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2130157 | 1.00 | RAF1 (0.48) | RAF1BRAFMAPK1KCNK3NAPEPLD | |
| SCHEMBL30795323 | 0.91 | NAMPT (0.44) | RAF1BRAFNAPEPLD | |
| SCHEMBL2130076 | 0.91 | NAMPT (0.44) | RAF1BRAFNAPEPLD | |
| SCHEMBL30796012 | 0.89 | PIK3CB (0.47) | NAPEPLDALDH1A1PIK3CBPKMTSHR | |
| SCHEMBL2130402 | 0.89 | PIK3CB (0.47) | NAPEPLDALDH1A1PIK3CBPKMTSHR | |
| SCHEMBL2130221 | 0.88 | PIK3CB (0.49) | NAPEPLDPIK3CBPKMTSHRCRHBP | |
| SCHEMBL2128993 | 0.88 | NAPEPLD (0.52) | NAPEPLDALDH1A1GAAPIK3CBPKM | |
| SCHEMBL2130723 | 0.87 | SRC (0.45) | NAPEPLDALDH1A1PIK3CBPKMTSHR | |
| SCHEMBL30795190 | 0.87 | SRC (0.45) | NAPEPLDALDH1A1PIK3CBPKMTSHR | |
| SCHEMBL2129704 | 0.86 | LMNA (0.52) | NAPEPLDALDH1A1PIK3CBPKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |